ArticleJournal of clinical & translational endocrinology2019
Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus.
Article in Journal of clinical & translational endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prevalence of Insomnia (Symptoms) in T2D and Association With Metabolic Parameters and Glycemic Control: Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2020Pooled it
- Lack of Efficacy of Suvorexant in People with Insomnia and Poorly Controlled Type 2 Diabetes.Nature and science of sleep · 2023Trial
- Association Between Glucocorticoid Exposure and Objective Sleep Architecture in Rheumatoid Arthritis: An Exploratory Pilot EEG Study.Journal of clinical medicine · 2026Article
- Suvorexant protects from ocular complications of diabetes in db/db mice.BMJ open diabetes research & care · 2026Article
- 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Association Between Hypnotics and Glycemic Variability Assessed by Continuous Glucose Monitoring Under Real-Life Conditions in Patients With Type 2 Diabetes: A Cross-Sectional Study.Journal of diabetes research · 2025Article
- Pharmacological and psychological approaches to insomnia treatment in cardiac patients: a narrative literature review.Frontiers in psychiatry · 2025Review
- Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective.Aging and disease · 2023Article
- Connecting insufficient sleep and insomnia with metabolic dysfunction.Annals of the New York Academy of Sciences · 2023Review
- Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations.Nature and science of sleep · 2023Review
- Body Weight and Metabolic Rate Changes in Narcolepsy: Current Knowledge and Future Directions.Metabolites · 2022Review
- Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon.Trends in neurosciences · 2022Review
- Diet and Physical Activity as Determinants of Continuously Measured Glucose Levels in Persons at High Risk of Type 2 Diabetes.Nutrients · 2022Article
- Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.Health psychology research · 2022Article
- Can treatment of obesity reduce depression or vice versa?Journal of psychiatry & neuroscience : JPN · 2021Article
- The Potential Role of Pancreatic γ-Aminobutyric Acid (GABA) in Diabetes Mellitus: A Critical Reappraisal.International journal of preventive medicine · 2021Review
- Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey.BMJ open · 2020Article
- Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.Neuroscience bulletin · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute and chronic insomnia can exacerbate type 2 diabetes mellitus (T2DM). We investigated suvorexant (an anti-insomnia drug that targets the orexin system) effects on sleep architecture and glucose metabolism in T2DM patients with insomnia. MATERIALS AND
methodsThis 7 day open-label, single-arm, intervention trial included 18 subjects with T2DM and insomnia. After 1 day acclimatization, daily glucose levels, sleep architecture, and autonomic nervous function were evaluated by continuous glucose monitoring (CGM), single-channel electroencephalography, and accelerometry, respectively.
resultsSuvorexant treatment for 3 days significantly increased total sleep time and sleep efficiency, with partial suppression of sympathetic nerve activity. CGM-measured 24 h mean glucose level decreased significantly from 157.7 ± 22.9 to 152.3 ± 17.8 mg/dL, especially in the early glucose surge after the midnight nadir (from 28.3 ± 15.0 to 18.2 ± 9.9 mg/dL), and until supper with a significant improvement in homeostasis model assessment of insulin resistance from 4.0 ± 2.8 to 2.9 ± 1.6, respectively.
conclusionsSuvorexant treatment for insomnia of subjects with T2DM significantly improved CGM-measured daily glycemic control, which was associated with changes in sympathomimetic tone and/or improved insulin sensitivity. The amelioration of insomnia may therefore be a target for improving glycemic control in T2DM patients with insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.